هل يجب على مرضى الرجفان الأذيني الذين لديهم عامل خطر إضافي واحد في درجة CHA2DS2-VASc (بعيدًا عن الجنس) تلقي مضادات التخثر الفموية؟

درس شاو وآخرون (Sun,) هذا السؤال.

www.synapsesocial.com/papers/69f0cfe2b606b7e8fdeb2f33 — DOI: https://doi.org/10.1016/j.jacc.2014.11.046

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Stroke Severity in Atrial Fibrillation· 1996 · 1,376 citations
2. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study· 2011 · 300 citations
3. The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review· 2013 · 57 citations
4. CHADS2 and CHA2DS2-VASc Scores in the Prediction of Clinical Outcomes in Patients With Atrial Fibrillation After Catheter Ablation